- Home
- LBTYB vs DYN Comparison
LBTYB vs DYN Comparison
Compare LBTYB & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYB | DYN |
|---|---|---|
| Founded | 2004 | 1984 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.8B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LBTYB | DYN |
|---|---|---|
| Price | $11.89 | $25.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $37.00 |
| AVG Volume (30 Days) | 2.7K | ★ 2.5M |
| Earning Date | 02-18-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $11,541,500,000.00 | N/A |
| Revenue This Year | $15.41 | N/A |
| Revenue Next Year | $3.03 | N/A |
| P/E Ratio | $12.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.20 | $11.65 |
| 52 Week High | $29.01 | $27.31 |
Technical Indicators
Market Signals| Indicator | LBTYB | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 43.93 | 56.28 |
| Support Level | $10.38 | $16.55 |
| Resistance Level | $12.16 | $26.62 |
| Average True Range (ATR) | 0.64 | 1.15 |
| MACD | 0.10 | -0.16 |
| Stochastic Oscillator | 28.46 | 49.18 |
Price Performance
Historical ComparisonAbout LBTYB Liberty Global Ltd. Class B
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.